



SELF-CERTIFICATION DECLARATION

ICANN 2026 New gTLD Program

Applicant Guidebook (V1-2025.12.16) | Appendix 1, Question 221 (Q5.2-1)

Self-Certifications SC5.2-1.1 through SC5.2-1.7

SELF-CERTIFICATION

The undersigned, being the Chief Operating Officer of BioNTech SE (the "Applying Entity"), hereby represents and warrants on behalf of BioNTech SE as follows:

SC5.2-1.1

BioNTech SE will, no later than delegation of the Top-Level Domain (TLD), establish a dedicated abuse point of contact responsible for addressing matters requiring expedited attention and providing a timely response to abuse complaints concerning any name registered in the TLD.

SC5.2-1.2

BioNTech SE will, no later than delegation of the TLD, establish, publish, and provide to ICANN the location of a mechanism for members of the public to submit reports of abuse in accordance with the current obligations of the Base RA and any Consensus Policies.

SC5.2-1.3

BioNTech SE has developed proposed measures for removal of orphan glue records for names removed from the zone when provided with evidence in written form that the glue is present in connection with malicious conduct (see Specification 6).

SC5.2-1.4

BioNTech SE has or will have at time of delegation, established policies for handling complaints regarding abuse. Such policies are to be maintained and posted publicly so that anyone can review the policies via the Internet and any other means deemed appropriate by BioNTech SE. BioNTech SE's policies at a minimum should contain appropriate confirmation of the receipt of the abuse report, the process of review of the report, and actions that will be taken if BioNTech SE confirms the report is legitimate.

SC5.2-1.5

BioNTech SE understands that DNS Abuse is Phishing, Malware, Botnets, Pharming and Spam (when used to deliver other forms of DNS Abuse). BioNTech SE understands and is prepared to contribute to the mitigation or disruption of DNS Abuse in domains in the TLD zone.

BioNTech SE
An der Goldgrube 12
55131 Mainz
Germany

Phone: +49 (0) 6131-90 84 0
Fax: +49 (0) 6131-90 84 390
info@biontech.de

Management Board:
Prof. Ugur Sahin, M.D.
Dr. Sierk Poetting
Prof. Özlem Türeci, M.D.
James Ryan, Ph.D.
Annemarie Hanekamp
Ramon Zapata-Gomez
Kylie Jimenez

Superv. Board Chairman:
Helmut W. Jeggler

Commercial Register
District court Mainz
HRB 48720
Tax ref. no: DE 263382495

Deutsche Bank
IBAN: DE50550700400030070700
SWIFT: DEUTDE5MXXX

SC5.2-1.6

BioNTech SE's abuse response capabilities are resourced appropriately to ensure a timely and adequate investigation and response to reports of DNS Abuse. This includes capabilities to receive and evaluate evidence of DNS Abuse in reports, and to take action to stop or disrupt the DNS Abuse.

SC5.2-1.7

BioNTech SE is prepared to conduct periodic scans of its zone to identify if domains are being used to perpetrate DNS Abuse, and to maintain statistical reports of the scans, the findings, and actions taken.

CERTIFICATION

The undersigned certifies that the foregoing statements are true, accurate, and complete to the best of the undersigned's knowledge and belief, and that the undersigned has authority to make these representations on behalf of BioNTech SE.

Executed on behalf of: BioNTech SE

Signature:  Signed by:
E78E248002F342F...

Name (printed): Sierk Poetting

Title: Chief Operating Officer

Date of Signature: Jul-15-2026

BioNTech SE
An der Goldgrube 12
55131 Mainz
Germany

Phone: +49 (0) 6131-90 84 0
Fax: +49 (0) 6131-90 84 390
info@biontech.de

Management Board:
Prof. Ugur Sahin, M.D.
Dr. Sierk Poetting
Prof. Özlem Türeci, M.D.
James Ryan, Ph.D.
Annemarie Hanekamp
Ramon Zapata-Gomez
Kylie Jimenez

Superv. Board Chairman:
Helmut W. Jeggler

Commercial Register
District court Mainz
HRB 48720
Tax ref. no: DE 263382495

Deutsche Bank
IBAN: DE50550700400030070700
SWIFT: DEUTDE33XXX